Forest Laboratories, FRX and Gedeon Richter Plc. announced
that Forest has submitted a New Drug Application (NDA) to the U.S. Food
and Drug Administration (FDA) for cariprazine, a potent dopamine D3/D2
receptor partial agonist with preferential binding to D3
receptors. Cariprazine was discovered by Gedeon Richter Plc and is
licensed to Forest Laboratories Inc., in the U.S. and Canada.
The application for the treatment of schizophrenia includes results from
three positive trials in over 1700 patients, two fixed dose studies with
active controls and one fixed-flexible placebo-controlled dose study
using the change from baseline in Positive and Negative Syndrome Scale
(PANSS) total score as primary efficacy endpoint.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in